Brought to you by 
BMS and Gilead work on HIV combination drug
Jun 2004
Executive Summary
Bristol-Myers Squibb and Gilead have formed a joint venture, Bristol-Myers Squibb & Gilead Sciences LLC, to develop and sell in the US a fixed-dosed combination of BMS' Sustiva and Gilead's Truvada, which combines two approved Gilead products Emtriva and Viread.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Contract
- Co-Promotion
- Joint Venture
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS and Gilead work on HIV combination drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice